Nuformix Advances Inhaled Lung Treatment, NXP002

Nuformix Plc (GB:NFX) has released an update.

Nuformix Plc, a pharmaceutical company specializing in drug repurposing for fibrosis and oncology, reports a reduced half-year loss before tax and continues progress on its inhaled treatment for fibrotic lung diseases, NXP002. The company has secured patents in Japan and Europe for NXP002 and received milestone payments from the sale of its NXP001 patent estate. With a lean operational model, Nuformix remains focused on generating data and securing partnerships for their novel drug candidates.

For further insights into GB:NFX stock, check out TipRanks’ Stock Analysis page.